The first sign of a pressure injury is often invisible to the human eye, a subtle change in tissue perfusion that precedes the reddened skin and, eventually, the open wound. This is the gap Rubitection aims to fill: a moment of detection that happens not in the clinic, but wherever a patient is sitting or lying down, measured by a handheld optical probe connected to a mobile app. For a problem the company cites as an $11 billion annual burden on the healthcare system, the goal is to move diagnosis from reactive to predictive [PitchBook, retrieved 2025].
Founded in 2011 by biomedical engineer Dr. Sanna Gaspard, the Pittsburgh-based company has taken the long road through academic research, government grants, and accelerator programs to reach its current point. Its core product, the Rubitect Assessment System (RAS), recently cleared a significant regulatory hurdle, receiving 510(k) Premarket Notification from the FDA, a key de-risking step for any medical device [Rubitection website, retrieved 2025]. The company has raised a total of $1.3 million, with a recent $409,000 equity crowdfunding round in May 2025, and is reportedly seeking an additional $2 million in seed funding [PitchBook, retrieved 2025] [Tracxn, retrieved 2025].
A PhD thesis turned into a patient monitor
The company's origin is a classic story of academic translation. Dr. Gaspard invented the core optical technology for early bedsore detection during her PhD work in Biomedical Engineering at Carnegie Mellon University, later founding Rubitection to commercialize it [Carnegie Mellon University, August 2013]. Her path reflects a funding strategy common in deep healthtech: a reliance on non-dilutive capital and institutional support to fund the lengthy development cycle. The company's investor and partner list reads like a map of the public-private innovation pipeline, featuring the NIH's SBIR/STTR programs, the Massachusetts Medical Device Development Center, and accelerators like Techstars and Luminate [Perplexity Sonar Pro Brief, retrieved 2025].
This foundation has supported a lean operation. The company lists an estimated five employees and has maintained a focus on proving the technology's clinical utility before scaling a sales force [LinkedIn, retrieved 2025]. The RAS system itself is a hardware-software combination. The handheld probe uses optical methods to assess skin for early signs of inflammation and changes in blood flow, with the accompanying software providing risk analytics, progression monitoring, and care plan management for clinicians [MTEC, retrieved 2025].
The wedge into a costly, chronic problem
Rubitection's initial market entry is focused squarely on pressure injuries, commonly known as bedsores. These wounds develop from prolonged pressure on the skin, typically in patients with limited mobility in settings like hospitals, nursing homes, and home care. The clinical standard of care remains manual, visual skin checks by caregivers,a method prone to human error and variability. The company's bet is that an objective, quantifiable measurement can catch tissue damage earlier, allowing for interventions that prevent costly and painful Stage 3 and 4 wounds.
Its projected market is substantial. Rubitection cites a $4.3 billion total addressable market for its low-risk FDA technology and projects sales reaching $290 million within six to seven years [Tracxn, retrieved 2025]. The financial projections attached to its fundraising efforts are ambitious, forecasting annual recurring revenue growing from an estimated $646,000 in 2022 to over $150 million by 2027 [Tracxn, retrieved 2025]. These figures underscore the venture-scale outcome the company is targeting, contingent on widespread adoption.
The competitive landscape is defined more by the absence of technology than by a crowded field. The primary alternative cited is manual assessment. The only named technological competitor is Bruin Biometrics' Provizio SEM Scanner, a handheld device that uses sub-epidermal moisture measurement to assess pressure injury risk. Rubitection's differentiation appears to rest on its optical approach and the integrated care management software platform.
| Aspect | Rubitection | Primary Alternative |
|---|---|---|
| Technology | Handheld optical probe & AI software | Manual visual assessment |
| Detection Method | Measures tissue perfusion & inflammation | Visual inspection for redness & skin breakdown |
| Regulatory Status | FDA 510(k) cleared | N/A (standard of care) |
| Key Claim | Objective, early detection before visible damage | Subjective, reliant on caregiver skill |
The path from clearance to the clinic
An FDA 510(k) clearance is a necessary gate, but it is not a guarantee of commercial success. The next twelve months will test Rubitection's ability to transition from a development-stage company to one with a commercial footprint. The company is running a beta testing and demo program, a critical step for gathering real-world clinical feedback and building case studies [MTEC, retrieved 2025]. Key milestones to watch will be the announcement of its first commercial contracts, likely with senior living facilities or home health agencies, and any data from clinical validation studies published in peer-reviewed journals.
The company also faces the classic challenges of any hardware-enabled software business in healthcare.
- Sales motion. Selling a physical device into regulated care settings is a slower, more expensive process than pure software sales. Rubitection will need to prove its system integrates smoothly into existing nurse workflows without adding significant time burden.
- Reimbursement. While the device may reduce overall treatment costs, securing consistent reimbursement from insurers for a new diagnostic tool is a separate, arduous battle that can make or market adoption.
- Clinical evidence. To move from a novel tool to a new standard of care, the company will need to build a robust library of clinical evidence demonstrating that using the RAS leads to statistically significant reductions in pressure injury incidence and severity, which in turn lowers hospitalization rates and costs.
The company's answer to these challenges appears to be its focus on the care management software layer. By positioning the RAS as a platform for monitoring skin health over time, not just a spot-check device, Rubitection aims to create ongoing value and stickiness within a care team.
The patient at the center of the scan
For all the talk of markets and mechanics, the fundamental promise of Rubitection's technology is human. It is aimed at a patient population often rendered silent by their condition: individuals with limited mobility due to spinal cord injury, advanced age, or critical illness. These are people for whom a preventable bedsore can mean months of painful treatment, increased risk of life-threatening infection, and a severe decline in quality of life.
The standard of care today is a caregiver's trained eye and hand, checking bony prominences for redness during a turn. It is a ritual of vigilance, but one limited by subjectivity and the fact that damage often begins beneath the skin's surface. If Rubitection's optical scan can reliably signal trouble days earlier, it could shift the paradigm from treating wounds to preserving skin integrity. That is the bet, not on a gadget, but on changing the trajectory of care for some of healthcare's most vulnerable patients. The next phase is about proving that the data from the probe translates into better, and more humane, outcomes at the bedside.
Sources
- [PitchBook, retrieved 2025] Rubitection 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/107197-84
- [Rubitection website, retrieved 2025] Rubitection | https://rubitection.com/
- [Tracxn, retrieved 2025] Rubitection - 2025 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/rubitection/__mlkzCktjauZ5krX0E5KDV2It-V_sKn0_rq7ES_0aiTY
- [Carnegie Mellon University, August 2013] Press Release: Carnegie Mellon Alumna Sanna Gaspard | https://www.cmu.edu/news/stories/archives/2013/august/aug12_sannagaspard.html
- [Perplexity Sonar Pro Brief, retrieved 2025] Rubitection company brief | [Summary from provided research]
- [MTEC, retrieved 2025] Rubitection | MTEC | https://mtec-sc.org/life-sciences/rubitection
- [LinkedIn, retrieved 2025] Rubitection Inc. | https://www.linkedin.com/company/rubitection-inc